2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene CAS 898566-17-1 Purity >98.0% (HPLC)

Short Description:

Chemical Name: 2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene

CAS: 898566-17-1

Purity: >98.0% (HPLC)

Appearance: White to Pale Yellow Crystalline Powder

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply Related Intermediates:
4-Fluorophenylboronic Acid CAS: 1765-93-1
2-(4-Fluorophenyl)thiophene CAS: 58861-48-6
2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone CAS: 32384-65-9
5-Iodo-2-Methylbenzoic Acid CAS 54811-38-0
2-(5-Bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene CAS: 1030825-20-7
2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene CAS: 898566-17-1
CAS: 842133-18-0
CAS: 928672-86-0

Chemical Properties:

Chemical Name	2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene
CAS Number	898566-17-1
CAT Number	RF-PI1501
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C18H14FIS
Molecular Weight	408.27
Melting Point	109.0~110.0℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Pale Yellow Crystalline Powder
Purity / Analysis Method	>98.0% (HPLC)
Loss on Drying	<1.00%
Total Impurities	<2.00%
Test Standard	Enterprise Standard

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene (CAS: 898566-17-1) is an antidiabetic agent and an intermediate of API (CAS: 842133-18-0). (CAS: 842133-18-0) is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and a candidate for the treatment of type 2 diabetes and obesity. (CAS: 842133-18-0) is a once daily oral diabetes drug, which works by inhibiting sodium glucose co-transporter 2 (SGLT2) as a new drug. (CAS: 842133-18-0) can lower blood glucose levels by interdicting the blood glucose reabsorption of the kidneys and increasing the excretion of blood glucose in urine. It is the first FDA approved inhibitor for SGLT2 and used to treat adult patients with type 2 diabetes.